Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics
Molecules · 05.08.2023 · 28 (15) · 5904
DOI: 10.3390/molecules28155904 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 05.08.2023. Verfasst von Juan Rong und 5 weiteren Autor:innen. Beteiligte Einrichtung: West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis C…. Hauptthemen laut MEDLINE: Isoflavones. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program of Science and Technology Department of Sichuan Province, 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Tectorigenin is a well-known natural flavonoid aglycone and an active component that exists in numerous plants. Growing evidence suggests that tectorigenin has multiple pharmacological effects, such as anticancer, antidiabetic, hepatoprotective, anti-inflammatory, antioxidative, antimicrobial, cardioprotective, and neuroprotective. These pharmacological properties provide the basis for the treatment of many kinds of illnesses, including several types of cancer, diabetes, hepatic fibrosis, osteoarthritis, Alzheimer’s disease, etc. The purpose of this paper is to provide a comprehensive summary and review of the sources, extraction and synthesis, pharmacological effects, toxicity, pharmacokinetics, and delivery strategy aspects of tectorigenin. Tectorigenin may exert certain cytotoxicity, which is related to the administration time and concentration. Pharmacokinetic studies have demonstrated that the main metabolic pathways in rats for tectorigenin are glucuronidation, sulfation, demethylation and methoxylation, but that it exhibits poor bioavailability. From our perspective, further research on tectorigenin should cover: exploring the pharmacological targets and mechanisms of action; finding an appropriate concentration to balance pharmacological effects and toxicity; attempting diversified delivery strategies to improve the bioavailability; and structural modification to obtain tectorigenin derivatives with higher pharmacological activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre and West China-Liverpool Biomedical Research Centre, West China…
- Advanced Mass Spectrometry Center, Research Core Facility, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
- Proteomics-Metabolomics Platform, Research Core Facility, West China-Washington Mitochondria and Metabolism Centre, Institutes for Systems Genetics, West China Hospital, Sichuan University, Chengdu 610041, China.
Förderung
- Program of Science and Technology Department of Sichuan Province
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
Zitieren
APA
Rong, J., Fu, F., Han, C., Wu, Y., Xia, Q., & Du, D. (2023). Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics. Molecules, 28(15), 5904. https://doi.org/10.3390/molecules28155904
Vancouver
Rong J, Fu F, Han C, Wu Y, Xia Q, Du D. Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics. Molecules. 2023;28(15):5904. doi:10.3390/molecules28155904
BibTeX
@article{Rong2023,
author = {Rong, Juan and Fu, Fei and Han, Chenxia and Wu, Yaling and Xia, Qing and Du, Dan},
title = {Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics},
journal = {Molecules},
year = {2023},
volume = {28},
number = {15},
pages = {5904},
doi = {10.3390/molecules28155904}
}
EUVIMED